KRAS and colorectal carcinoma: Furthermore, mutant KRAS, found in 30–50% of CRC tumors, influences the activity of the RAF/MEK/ERK and PI3K/PTEN/AKT signaling pathways, leading to cascade of events that fuel worse overall survival [8].